NOVEL INHIBITORS OF FUNGAL ASPARTIC PROTEINASES
真菌天冬氨酸蛋白酶的新型抑制剂
基本信息
- 批准号:6312013
- 负责人:
- 金额:$ 21.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-01-01 至 2003-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: Immunocompromised patients are susceptible to infection by
organisms that are typically cleared by the normal host immune system. Candida
albicans (CA) infection leads to several moderate to life threatening or
disseminated clinical diseases. Agents that could prevent this infection would
help relieve suffering in patients undergoing transplantation, chemotherapy,
and fighting AIDS. Proteases secreted by CA aid in penetration through the
extracellular matrix to spread infection. These proteases are believed to be
virulence factors, and are members of the aspartic proteinase family. It is
known that pepstatin, a general inhibitor of aspartic proteinases, will
suppress growth of CA. We have recently determined the three-dimensional
structure of a related fungal enzyme, yeast proteinase A (YprA) in complex with
its natural protein inhibitor, IA-3. This new complex reveals novel features of
the inhibition that we proposed to explore further in this project. IA-3 is
completely unfolded in solution, as we have established by NMR analysis. By
understanding the interactions between YprA and IA-3, we plan to design new
inhibitors targeted to the closely related protease from CA. We will achieve
this objective through four specific aims. In Aim 1, we will create mutants of
the IA-3 to aid in studies of the helix-coil transition and the physical
interaction with enzyme through fluorescence energy transfer and
continuous-flow micro-mixing procedures. In Aim 2, mutants will be designed to
determine critical points of interaction, which could result in simplification
of the inhibitor structure. Based on the interactions of the mutants with YprA,
we will select some for studies by NMR in both Aims 1 and 2 to determine the
dynamics of the unbound state and changes in structure upon binding. In Aim 3
we will make changes in the structure to permit binding to and inhibition of
the Candida albicans protease of similar structure and function. In Specific
Aim 4 we will exploit the new information provided by the IA-3/YprA complex to
aid in design of small molecule inhibitors that achieve specificity through a
new mechanism of binding. Compounds developed through this program will be
tested against Candida albicans in culture.
描述:免疫功能低下的患者容易感染
通常由正常的宿主免疫系统清除的生物体。念珠菌
白色念珠菌(CA)感染导致几个中度到危及生命的或
播散性临床疾病。可以预防这种感染的药物将
帮助减轻接受移植、化疗、
和抗击艾滋病。CA分泌的蛋白酶有助于穿透
细胞外基质传播感染。这些蛋白水解酶被认为是
毒力因子,是天冬氨酸蛋白酶家族的成员。它是
已知胃抑素,一种天冬氨酸蛋白酶的通用抑制剂,将
抑制CA的生长。我们最近已经确定了三维
一种与真菌相关的酵母酶A(YprA)的结构
它的天然蛋白质抑制剂IA-3。这个新的综合体展示了
我们建议在这个项目中进一步探索的抑制。IA-3 IS
完全在溶液中展开,正如我们通过核磁共振分析所确定的那样。通过
了解YprA和IA-3之间的相互作用,我们计划设计新的
针对CA密切相关的蛋白水解酶的抑制剂。我们将实现
这一目标通过四个具体目标实现。在目标1中,我们将创建突变体
IA-3帮助研究螺旋-线圈转变和物理
与酶的相互作用通过荧光能量转移和
连续流微混合程序。在目标2中,突变体将被设计成
确定相互作用的关键点,这可能会导致简化
抑制物结构。基于突变体与YprA的相互作用,
我们将在AIMS 1和AIMS 2中选择一些用于核磁共振研究,以确定
未结合状态的动力学和结合时结构的变化。在AIM 3中
我们将在结构上进行改变,以允许结合和抑制
具有相似结构和功能的白色念珠菌蛋白酶。具体而言
目标4我们将利用IA-3/YprA综合体提供的新信息来
协助设计小分子抑制剂,通过
新的约束机制。通过这一计划开发的化合物将是
在培养中对白色念珠菌进行了检测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ben M. Dunn其他文献
HIV protease and malarial plasmepsin inhibitors with hydroxymethylcarbonyl isostere
具有羟甲基羰基电子等排体的 HIV 蛋白酶和疟疾血浆蛋白酶抑制剂
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Koushi Hidaka;Tooru Kimura;Yumi Tsuchiya;Mami Kamiya;Ernesto Freire;Ben M. Dunn;Yoshio Hayashi;Yoshiaki Kiso - 通讯作者:
Yoshiaki Kiso
Backbone 1H, 13C, and 15N chemical shift assignment for HIV-1 protease subtypes and multi-drug resistant variant MDR 769
- DOI:
10.1007/s12104-012-9409-7 - 发表时间:
2012-07-01 - 期刊:
- 影响因子:0.600
- 作者:
Xi Huang;Ian Mitchelle S. de Vera;Angelo M. Veloro;James R. Rocca;Carlos Simmerling;Ben M. Dunn;Gail E. Fanucci - 通讯作者:
Gail E. Fanucci
Kinetics of Woodward's Reagent K Hydrolysis and Reaction with Staphylococcal Nuclease
- DOI:
10.1016/s0021-9258(19)42532-5 - 发表时间:
1974-06-25 - 期刊:
- 影响因子:
- 作者:
Ben M. Dunn;Christian B. Anfinsen;Richard I. Shrager - 通讯作者:
Richard I. Shrager
Correction to “Inhibitor Complexes of the Pseudomonas Serine-Carboxyl Proteinase”
对“假单胞菌丝氨酸羧基蛋白酶抑制剂复合物”的更正
- DOI:
10.1021/acs.biochem.8b01130 - 发表时间:
2018 - 期刊:
- 影响因子:2.9
- 作者:
Alexander Wlodawer;Mi Li;Alla Gustchina;Zbigniew Dauter;Kenichi Uchida;Hiroshi Oyama;Nathan E. Goldfarb;Ben M. Dunn;Kohei Oda - 通讯作者:
Kohei Oda
α-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases
- DOI:
10.1016/j.bmc.2009.06.065 - 发表时间:
2009-08-15 - 期刊:
- 影响因子:
- 作者:
Kristina M. Orrling;Melissa R. Marzahn;Hugo Gutiérrez-de-Terán;Johan Åqvist;Ben M. Dunn;Mats Larhed - 通讯作者:
Mats Larhed
Ben M. Dunn的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ben M. Dunn', 18)}}的其他基金
NOVEL INHIBITORS OF FUNGAL ASPARTIC PROTEINASES
真菌天冬氨酸蛋白酶的新型抑制剂
- 批准号:
6626411 - 财政年份:2001
- 资助金额:
$ 21.45万 - 项目类别:
NOVEL INHIBITORS OF FUNGAL ASPARTIC PROTEINASES
真菌天冬氨酸蛋白酶的新型抑制剂
- 批准号:
6488787 - 财政年份:2001
- 资助金额:
$ 21.45万 - 项目类别:
HEPATITIS C VIRUS NS3 PROTEASE--ACTIVE SITE
丙型肝炎病毒 NS3 蛋白酶——活性位点
- 批准号:
2330570 - 财政年份:1996
- 资助金额:
$ 21.45万 - 项目类别: